MVZ Bruck, Linck, Buschmann
- Address
- Europaring 42, 53123 Bonn, Germany
MVZ Bruck, Linck, Buschmann - Gastrointestinal Oncology Research
MVZ Bruck, Linck, Buschmann is a specialized medical research center focused on advancing clinical care in gastrointestinal malignancies. The center demonstrates particular expertise in colorectal cancer research, utilizing cutting-edge molecular diagnostic approaches to optimize treatment strategies for early-stage disease.
- Stage II colon and rectal cancer treatment optimization
- Circulating tumor DNA (ctDNA) biomarker research
- Adjuvant therapy decision-making in early-stage colorectal cancer
The center's research emphasizes precision oncology approaches, particularly investigating the role of liquid biopsy and ctDNA monitoring to identify patients who may benefit from adjuvant chemotherapy after surgical resection. Their work contributes to personalized treatment algorithms that balance therapeutic benefit with quality of life considerations in UICC stage II colorectal cancer patients.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 1 by active trials.
- 1BioNTech SE1active
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
No repeated partnerships found.
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 2 161 other sites in Germany
Therapeutic Area Benchmark — Germany
Select a therapeutic area to compare against other sites in Germany.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Germany
Market Share
Country: Germany
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in MVZ Bruck, Linck, Buschmann
lock Showing 1 of 2 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Phase III, multisite, double-blinded randomized trial of BNT327 in combination with chemotherapy (etoposide/carboplatin) compared to atezolizumab in combination with chemotherapy (etoposide/carboplatin) in participants with first-line extensive-stage small-cell lung cancer | BioNTech SE | Phase III | Recruiting | Feb 2026 | — |
IMP list
lock Showing 1 of 6 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Atezolizumab | 1 | Unknown | 2026-02-04 | 2026-02-04 |
Request feasibility information
Ask this centre about capacity, equipment and patient population.
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.